10:14 ET -- Moderna Inc. is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Moderna said its experimental vaccine significantly reduced the risk of a viral respiratory disease among older adults in a large clinical trial, the latest promising sign in drugmakers' efforts to fight the deadly RSV virus. The company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus. If regulators approve the vaccine, it could become available by early 2024. Moderna's RSV vaccine was 83.7% effective against lower-respiratory diseases caused by RSV in the study. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

January 18, 2023 10:29 ET (15:29 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023 Click aqui para mais gráficos Moderna.